Semaglutide Reduces Medical Costs: One-Year Economic Impact Analysis

One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hospitalizations, ER visits, and complications despite high drug cost.

Arora, Prachi et al.·Expert review of pharmacoeconomics & outcomes research·2025·Moderate Evidencecohort
RPEP-09983CohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=not specified
Participants
US adults with obesity or overweight and ≥1 obesity-related complication

What This Study Found

One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hospitalizations, ER visits, and complications despite high drug cost.

Key Numbers

Semaglutide 2.4 mg once weekly. Costs evaluated excluding pharmacy. Patients had obesity or overweight with ≥1 obesity-related complication.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hosp
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
Published In:
Expert review of pharmacoeconomics & outcomes research, 25(9), 1345-1355 (2025)
Database ID:
RPEP-09983

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hospitalizations, ER visits, and complications despite high drug cost.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09983·https://rethinkpeptides.com/research/RPEP-09983

APA

Arora, Prachi; Michalak, Wojciech; Zhao, Zhenxiang; Fiasconaro, Megan; Hong, Yu; Zhao, Xin; Ó Hartaigh, Bríain; Alvarez, Sara; Fitch, Angela. (2025). Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.. Expert review of pharmacoeconomics & outcomes research, 25(9), 1345-1355. https://doi.org/10.1080/14737167.2025.2570688

MLA

Arora, Prachi, et al. "Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.." Expert review of pharmacoeconomics & outcomes research, 2025. https://doi.org/10.1080/14737167.2025.2570688

RethinkPeptides

RethinkPeptides Research Database. "Effects of semaglutide on one-year medical costs among patie..." RPEP-09983. Retrieved from https://rethinkpeptides.com/research/arora-2025-effects-of-semaglutide-on

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.